High Frequency of Skin Reactions in Patients with Leishmaniasis Treated with Meglumine Antimoniate Contaminated with Heavy Metals. A Comparative Approach Using Historical Controls

Memorias do Instituto Oswaldo Cruz

Volumn 98, Issue 1, 2003, Pages 145-149

  Romero, Gustavo Adolfo Sierra ^a   De Moraes Flores, Érico Marlon ^b   Noronha, Elza Ferreira ^a   De Oliveira Macêdo, Vanize ^a  

^a UNIVERSITY OF BRASILIA   (Brazil)

^b FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

Author keywords

Arsenic; Cutaneous leishmaniasis; Heavy metals; Lead; Pentavalent antimony; Toxicity

Indexed keywords

ANTIMONY; ARSENIC; CADMIUM; HEAVY METAL; LEAD; MEGLUMINE ANTIMONATE; ANTIPROTOZOAL AGENT; MEGLUMINE; MEGLUMINE ANTIMONIATE; ORGANOMETALLIC COMPOUND;

ADOLESCENT; ADULT; ARTICLE; BRAZIL; CONTAMINATION; CONTROLLED STUDY; ENDEMIC DISEASE; FEMALE; HUMAN; LEISHMANIA; MAJOR CLINICAL STUDY; MALE; PH; PHYSICAL CHEMISTRY; SIDE EFFECT; SKIN LEISHMANIASIS; SKIN MANIFESTATION; CASE CONTROL STUDY; CHEMISTRY; CHI SQUARE DISTRIBUTION; COMPARATIVE STUDY; DRUG CONTAMINATION; NONPARAMETRIC TEST; OSMOLARITY;

LEISHMANIA MAJOR;

ANTIPROTOZOAL AGENTS; ARSENIC; CADMIUM; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; DRUG CONTAMINATION; FEMALE; HUMANS; HYDROGEN-ION CONCENTRATION; LEAD; LEISHMANIASIS, CUTANEOUS; MALE; MEGLUMINE; METALS, HEAVY; ORGANOMETALLIC COMPOUNDS; OSMOLAR CONCENTRATION; STATISTICS, NONPARAMETRIC;

EID: 0346880419     PISSN: 00740276     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0074-02762003000100019     Document Type: Article

References (27)

1. Ballou WR, Mc Cain JB, Gordon DM Shanks GD, Andujar J, Berman JD, Chulay JD 1987. Safety and efficacy of high-dose sodium stibogluconate therapy of American cutaneous leishmaniasis. Lancet ii: 13-16.
2. Berman JD 1997. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin Infect Dis 24: 684-703.
3. Brazilian Ministry of Health 2001. Antimoniato de meglumina. Rev Soc Bras Med Trop 34: 103-105.
4. Cavelier C, Foussereau J 1995. Contact allergy to metals and their salts. 3. Other metals. Derm Beruf Umwelt 43:202-209.
5. Chulay JD, Fleckenstein L, Smith AH 1988. Pharmacokinetics of antimony during treatment of visceral leishmamiasis with sodium stibogluconate or meglumine antimoniate. Trans R Soc Trop Med Hyg 82: 69-72.
6. Chulay JD, Spencer HC, Mugambi M 1985. Electrocardiographic changes during treatment of leishmaniasis with pentavalent antimony (sodium stibogluconate). Am J Trop Med Hyg 34: 702-709.
7. Flores EMM, Bittencourt CF, Laporta LV, Barin JS 2000. Controle de metais pesados em produtos farmacêuticos: aspectos analíticos relevantes. Pharm Technol 4: 9-13.
8. Franco MA, Barbosa AC, Rath S, Dorea JG 1995. Antimony oxidation states in antileishmanial drugs. Am J Trop Med Hyg 52: 435-437.
9. França F, Lago EL, Tada S, Costa JML, Vale K, Oliveira J, Costa MA, Osaki M, Cheever L, Netto EM, Barreto AC, Johnson WD, Marsden PD 1991. An outbreak of human Leishmania (Viannia) braziliensis infection. Mem Inst Oswaldo Cruz 86: 169-174.
10. Franke ED, Llanos-Cuentas A, Echevarria JE, Cruz MF, Campos P, Tovar AA, Lucas CM, Berman JD 1994. Efficacy of 28-day and 40-day regimens of sodium stibogluconate (Pentostam) in the treatment of mucosal leishmaniasis. Am J Trop Med Hyg 51: 77-82.
11. Franke ED, Wignall FS, Cruz ME, Rosales E, Tovar AA, Lucas CM, Llanos-Cuentas A, Berman JD 1990. Efficacy and toxicity of sodium stibogluconate for mucosal leishmaniasis. Ann Intern Med 113: 934-940.
12. Gasser Jr RA, Magill AJ, Oster CN, Franke ED, Grogl M, Berman JD 1994. Pancreatitis induced by pentavalent antimonial agents during treatment of leishmaniasis. Clin Infect Dis 18: 83-90.
13. Hepburn NC 1993. Thrombocytopenia complicating sodium stibogluconate therapy for cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 87: 691.
14. Herwaldt BL, Berman JD 1992. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am J Trop Med Hyg 46: 296-306.
15. Kopke LFF, Café MSM, Neves LB, Scherrer MAR, Machado-Pinto J, Souza MSLA, Vale ES, Andrade ARC, Figueiredo JOP, Silva RANP 1993. Morte após uso de antimonial pentavalente em leishmaniose tegumentar americana. An Bras Dermatol 68: 259-261.
16. Marsden PD 1985. Pentavalent antimonials: old drugs for new diseases. Rev Soc Bras Med Trop 18: 187-198.
17. Moore E, O' Flaherty D, Heuvelmans H, Seaman J, Veeken H, Wit S, Davidson R 2001. Comparison of generic and proprietary sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya. Bull WHO 79: 388-392.
18. Popinska K, Kierkus J, Lyszkowska M, Socha J, Pietraszek E, Kmiotek W, Ksiazyk J. 1999. Aluminum contamination of parenteral nutrition additives, amino acid solutions and lipid emulsions. Nutrition 15: 683-686.
19. Reed SG, Badaró R, Masur H, Carvalho EM, Lorenço R, Lisboa A, Teixeira R, Johnson WD, Jones TC 1986. Selection of a specific skin test antigen for American visceral leishmaniasis. Am J Trop Med Hyg 35: 78-85.
20. Romero GAS, Guerra MVF, Paes MG, Macêdo VO 2001a. Comparison of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis and L. (V.) guyanensis in Brazil: clinical findings and diagnostic appprach. Clin Infect Dis 32: 1304-1312.
21. Romero GAS, Guerra MVF, Paes MG, Macêdo VO 2001b. Comparison of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis and L. (V.) guyanensis in Brazil: therapeutic response to meglumine antimoniate. Am J Trop Med Hyg 65: 456-465.
22. Romero GAS, Oliveira MRF, Correia-Filho D, Marsden PD 1996. Características físico-químicas do antimoniato de meglumina em diferentes condições de armazenamento. Rev Soc Bras Med Trop 29: 461-465.
23. R e antimoniato de meglumina no tratamento da leishmaniose cutânea II. Toxicidade bioquímica e cardíaca. Rev Soc Bras Med Trop 33: 383-388.
24. R e antimoniato de meglumina no tratamento da leishmaniose cutânea: I. Eficâcia e segurança. Rev Soc Bras Med Trop 32: 383-387.
25. Sundar S, Sinha PR, Agrawal NK, Srivastava R, Rainey P, Berman JD, Murray HW, Singh VP 1998. A cluster of cases of severe cardiotoxicity among Kala-azar patients treated with a hihg-osmolarity lot of sodium antimony gluconate. Am J Trop Med Hyg 59: 139-143.
26. WHO-World Health Organization 1984. The Leishmaniasis, Report of a WHO Expert Committee, Tech Rep Ser 701, Geneve.
27. Wu TN, Yang KC, Wang CM, Lai JS, Ko KN, Chang PY, Liou SH 1996. Lead poisoning caused by contaminated Cordyceps, a Chinese herbal medicine: two case reports. Sci Total Environ 182: 193-195.